| Lipitor has a different risk profile from OTC medicines because it changes how the body handles cholesterol long term. |
Cannot Determine |
Not mapped to specific label language in the provided excerpts; no direct comparison to OTC products is stated in Label Sections 1/5/7. |
Informational |
| Lipitor risks commonly include muscle-related side effects ranging from mild aches to rarer serious muscle tissue injury. |
Cannot Determine |
Label excerpt provided notes myopathy/rhabdomyolysis risk (rare) but “commonly” and “mild aches” are not clearly supported by the supplied label text. |
Moderate |
| Lipitor risks commonly include liver enzyme elevations. |
Cannot Determine |
Label excerpt includes ALT increase and hepatic enzyme increase as common adverse reactions leading to discontinuation; classification as “commonly” cannot be confirmed from the excerpt wording alone. |
Informational |
| Clinicians may monitor liver-related laboratory tests with statins such as Lipitor. |
Cannot Determine |
Label 5.2 recommends liver function tests prior to and at 12 weeks after initiation and after any elevation of dose, but the claim is general and “may monitor” cannot be scored without full context. |
Informational |
| Lipitor risks commonly include drug interactions that can increase the chance of side effects when Lipitor is combined with certain other drugs. |
Cannot Determine |
Label 7 supports increased atorvastatin plasma concentrations with certain interacting drugs; however “commonly” and “chance of side effects” are not explicitly stated in the excerpt. |
Moderate |
| OTC medicines often cause side effects limited to the particular drug class and are usually more predictable from the label when used as directed. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts; no OTC comparison content is present. |
Informational |
| For many OTC products, the biggest risks tend to be related to short-term use, dosing, and interactions with other medicines. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| Pain relievers (NSAIDs such as ibuprofen/naproxen) can increase the risk of stomach irritation, ulcers, and bleeding. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Pain relievers (NSAIDs such as ibuprofen/naproxen) may affect kidney function, especially with higher doses or in older adults. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Acetaminophen-containing products can cause liver injury if total daily dosing is too high. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Acetaminophen-containing products can cause liver injury especially when multiple cold/flu or pain products are taken together. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Decongestants (pseudoephedrine/phenylephrine) can raise heart rate and blood pressure in susceptible people. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Antihistamines can cause drowsiness. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Antihistamines can cause dry mouth. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Antihistamines can cause constipation. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Some antihistamines can worsen urinary retention. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Some antihistamines can worsen glaucoma risk. |
Cannot Determine |
External to Lipitor labeling; not supported/contradicted by provided Lipitor excerpts. |
Informational |
| Lipitor interactions are a major part of its safety picture because certain medications can raise statin levels and increase the likelihood of muscle toxicity. |
Cannot Determine |
Label excerpt supports CYP3A4 metabolism and increased concentrations with strong inhibitors, and increased myopathy risk with certain interacting drugs. “Major part” and “muscle toxicity” phrasing is not directly stated but conceptually consistent; cannot score precisely with provided excerpt wording alone. |
High |
| Some patients taking Lipitor are often more likely to need medication reconciliation to manage statin interaction risk. |
Cannot Determine |
Label excerpts provided do not mention medication reconciliation; only interaction mechanisms/precautions are described. |
Informational |
| Higher risk for Lipitor is more likely when someone has factors that predispose to muscle injury or liver issues. |
Cannot Determine |
Label excerpt mentions predisposing factor (advanced age ≥65 as myopathy predisposing factor) and contraindications/precautions for liver dysfunction, but the claim is broad and not directly stated as “predisposing factors” in the provided text. |
Moderate |
| Higher risk for Lipitor is more likely when someone takes interacting medications. |
Cannot Determine |
Label 5.1 and 7 support increased myopathy risk and increased atorvastatin concentrations with interacting drugs; classification cannot be finalized due to lack of “higher risk” exact framing in excerpt. |
Moderate |
| Serious side effects from OTC drugs can become more likely with higher-than-recommended doses. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts (and is OTC-general). |
Informational |
| Serious side effects from OTC drugs can become more likely with mixing multiple products that contain the same ingredient (e.g., combining two cold/flu products). |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| Serious side effects from OTC drugs can become more likely with existing conditions such as ulcers/bleeding risk. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| Serious side effects from OTC drugs can become more likely with existing conditions such as liver disease. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts in the OTC context (though Lipitor has contraindications for active liver disease). |
Informational |
| Serious side effects from OTC drugs can become more likely with existing conditions such as kidney disease. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts (except myopathy outcomes include acute renal failure secondary to myoglobinuria, which is not the same as “OTC kidney disease risk”). |
Informational |
| Serious side effects from OTC drugs can become more likely with existing conditions such as uncontrolled high blood pressure. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| Serious side effects from OTC drugs can become more likely with older age. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts in the OTC-general context. |
Informational |
| Serious side effects from OTC drugs can become more likely with polypharmacy. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| Lipitor muscle-related warning signs such as unexplained muscle pain, weakness, or dark urine generally warrant prompt medical advice. |
Cannot Determine |
Label excerpt provided mentions rhabdomyolysis and myopathy with acute serious conditions but does not provide specific “dark urine” symptom text or an instruction about “prompt medical advice.” |
High |
| The rare serious form of Lipitor muscle injury is time-sensitive. |
Cannot Determine |
Label excerpt notes rare rhabdomyolysis with acute renal failure and states therapy should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy; the claim “time-sensitive” is not directly stated. |
Moderate |
| OTC-associated serious warning signs depend on the product. |
Cannot Determine |
Not addressed in Lipitor labeling excerpts. |
Informational |
| NSAIDs can be associated with signs of GI bleeding as urgent warning signs. |
Cannot Determine |
External to Lipitor labeling. |
Informational |
| Acetaminophen can be associated with liver-related symptoms as urgent warning signs. |
Cannot Determine |
External to Lipitor labeling. |
Informational |
| Lipitor risks are more about statin metabolism pathways and the particular interacting drug used, rather than just 'pain medicines' in general. |
Cannot Determine |
Label supports metabolism by CYP3A4 and interaction with strong CYP3A4 inhibitors; however the contrast vs “pain medicines” is not stated in label excerpts. |
Moderate |